Menarini Group is the largest Italian owned Pharmaceutical Group. The company has sales of over 2,4 billion euros and over 12,000 staff worldwide. The company spends over 122 million euros per annum on research and development in the following fields: cardiovascular, oncology, pain, inflammation and asthma.

The group has a range of compounds and biological entities in it's clinical pipeline, developed in-house or in-licensed. We currently have several biologic entities (Cardiovascular and Oncology) at late stage development (Phase 3) in our pipeline and we are interested in adding to this portfolio by in-licensing particularly in the previously mentioned therapeutic areas, primarily focussing on large molecules to enhance the portfolio.

Menarini Biotech is an integral part of the group and assists our licensing and R&D functions in the evaluation and selection of in-licensing opportunities. We are a centre of excellence for biotechnology in Italy.

We have our own development and manufacturing facilities for cell culture and microbial fermentation derived biologics and we can also provide services as CMO in cGMP biologics/biosimilars API purified bulks production for (non) clinical trials and in analytical methods development/therapeutic proteins characterization. We have international experts and an experienced team who have developed and commercialised many biologic products and look forward to successfully commercialising your product.

Menarini has a deep-rooted history and a strategy of international agreements with other companies through the licensing of innovative products. Menarini Biotech also provides consultancy and contract development and manufacturing.